DRUG NAME: Amoxicillin + Clavulanic Acid

---

Therapeutic Class:

---

Subclass:

---

Speciality:

• Primary Speciality: Infectious Disease
• Also used in: ENT, Pulmonology, Paediatrics

---

Schedule (India):

---

Route(s):

• Oral (film-coated tablets, dispersible tablets, dry syrup/powder for oral suspension)
• Intravenous (IV) — slow IV injection or IV infusion (powder for reconstitution)

---

Biosimilar Status:

---

Formulations Available in India:

A. Single-Combination Formulations (Amoxicillin + Clavulanate)

Oral Tablets (Film-Coated):

Dispersible Tablets (DT) — primarily for paediatric use:

Dry Syrup / Powder for Oral Suspension:

B. Clinically Relevant Fixed-Dose Combinations (FDCs) Available in India

• Amoxicillin + Clavulanate + Lactobacillus (probiotic): Available from multiple manufacturers. Intended to reduce antibiotic-associated diarrhoea. Common in Indian market; clinical benefit of the probiotic component at the included dose is debated.

• Amoxicillin + Clavulanate + anti-inflammatory/analgesic combinations (e.g., with Diclofenac, Serratiopeptidase in some irrational formulations) — several such irrational FDCs were banned under CDSCO orders of 2016 and 2018. Prescribers should verify that any FDC prescribed is a currently approved, rational combination.

---

PHARMACOKINETICS

Drug Transporter Profile:

• Amoxicillin is a substrate of:
• • PepT1 (SLC15A1) — intestinal peptide transporter responsible for its good oral absorption
  • OAT1 (SLC22A6) and OAT3 (SLC22A8) — renal organic anion transporters mediating active tubular secretion
• Amoxicillin is not a clinically significant substrate, inhibitor, or inducer of P-glycoprotein (P-gp), OATP1B1/1B3, BCRP, OCT2, or MATE1/2.
• Clavulanic acid — no clinically significant drug transporter interactions identified.
• Neither component is a significant CYP450 substrate, inhibitor, or inducer.

---

Population Pharmacokinetic Notes

---

ADULT INDICATIONS + DOSING

1. Is antibiotic therapy indicated at all? (Most URTIs are viral.)
2. Would amoxicillin alone suffice? (For confirmed Streptococcal pharyngitis, uncomplicated pneumococcal pneumonia — amoxicillin alone is preferred; clavulanate adds no value against organisms that don’t produce beta-lactamase.)
3. Is culture and sensitivity available to guide therapy?

---

• Oral: Max 875 mg amoxicillin per dose; Max 1750 mg amoxicillin per day (with BD regimen) or 1500 mg/day (with TDS regimen). Max clavulanate: 375 mg per day (oral).
• IV: Max 1000 mg amoxicillin per dose; Max 4000 mg amoxicillin per day (q6h regimen). Max clavulanate: 800 mg per day (IV).
• Starting dose: Not applicable — antibiotics do not require titration. Full therapeutic dose from the first dose.
• Titration: Not applicable.

---

Primary Indications (Approved / Standard in India)

---

Indication 1: ACUTE BACTERIAL SINUSITIS (ABS)

Mandatory Clinical Notes:

1. When to prefer this drug over alternatives: Amoxicillin + Clavulanate is recommended as first-line for moderate-severe ABS or when first-line amoxicillin alone has failed after 72 hours. It is preferred over amoxicillin alone in areas with high prevalence of beta-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis. API Textbook and ICMR AMR data support this approach in Indian practice.
2. When NOT to use: Do NOT prescribe for viral rhinosinusitis (the vast majority of cases). Bacterial sinusitis should be suspected only if symptoms persist ≥10 days without improvement, or worsen after initial improvement (“double sickening”), or present with severe onset (high fever ≥39°C + purulent nasal discharge for ≥3 consecutive days). Do NOT use if the patient has confirmed penicillin allergy (see Contraindications).
3. NLEM India status: ✅ Included in NLEM India 2022 (Tablet 500 mg + 125 mg; Injection 1000 mg + 200 mg).
4. Time to expected clinical response: Improvement expected within 48–72 hours of starting therapy. If no improvement by 72 hours, reassess diagnosis and consider treatment failure.
5. Treatment failure criteria: No improvement or worsening of symptoms at 72 hours. Switch to: respiratory fluoroquinolone (levofloxacin 500 mg OD or moxifloxacin 400 mg OD) or refer to ENT specialist. Obtain culture via endoscopic sinus aspiration if available.
6. Mandatory baseline investigations: ⚠️ MANDATORY: Confirm no history of penicillin/beta-lactam allergy (always ask before prescribing). RECOMMENDED: No routine labs needed for uncomplicated outpatient ABS. CT/MRI sinuses not required for initial episode (clinical diagnosis).
7. Specialist initiation: Not required — appropriate for primary care prescribing. Refer to ENT if: recurrent (≥4 episodes/year), complications suspected (orbital, intracranial), or treatment failure with second-line agent.
8. Indian guideline source: API Textbook of Medicine (ENT infections chapter); ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019).
9. Key safety warning: ⚠️ Hepatotoxicity (cholestatic jaundice) is more common with amoxicillin-clavulanate than with amoxicillin alone — risk increases with courses >14 days and in elderly males. Keep duration as short as clinically effective.
10. Dose adjustment scenarios: Renal impairment (eGFR <30 mL/min) — see Renal Adjustment section. Elderly — dose per renal function. Hepatic impairment — use with caution, monitor LFTs.

---

Indication 2: ACUTE OTITIS MEDIA (AOM) — Adults

Mandatory Clinical Notes:

1. When to prefer: Second-line after amoxicillin alone fails, OR first-line if: recurrent AOM, recent antibiotic exposure (within 30 days), or high local prevalence of beta-lactamase-producing H. influenzae. AOM is more commonly a paediatric indication; adult AOM should prompt evaluation for underlying pathology.
2. When NOT to use: Do NOT use for otitis media with effusion (OME) — this is usually non-infectious and does not require antibiotics. Do NOT use for otitis externa (topical therapy preferred).
3. NLEM India: ✅ Yes.
4. Time to response: 48–72 hours. If tympanic membrane bulging persists or symptoms worsen, consider myringotomy (ENT referral) and culture.
5. Treatment failure: Refer to ENT for tympanocentesis/culture. Consider respiratory fluoroquinolone or ceftriaxone IM.
6. Baseline investigations: MANDATORY: Otoscopic examination. Allergy history. RECOMMENDED: Audiometry if hearing loss suspected.
7. Specialist initiation: Not required for uncomplicated AOM. ENT referral for recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months), complications (mastoiditis, labyrinthitis, facial nerve palsy), or treatment failure.
8. Indian guideline: API Textbook; IAP Guidelines (for paediatric AOM — see paediatric section).
9. Safety warning: Same hepatotoxicity caution as above.
10. Dose adjustment: Renal impairment — see Renal Adjustment.

---

Indication 3: COMMUNITY-ACQUIRED PNEUMONIA (CAP) — Mild to Moderate

Mandatory Clinical Notes:

1. When to prefer: Amoxicillin + Clavulanate is recommended as first-line for outpatient CAP in Indian adults without comorbidities, OR as part of combination therapy for hospitalised non-severe CAP per API Textbook and ICMR guidelines. The addition of clavulanate over plain amoxicillin is justified by the high prevalence of beta-lactamase-producing H. influenzae and mixed infections in Indian settings.
2. 💡 For hospitalised CAP, combine with a macrolide (azithromycin 500 mg OD) or doxycycline (100 mg BD) to cover atypical organisms (Mycoplasma, Chlamydophila, Legionella). Amoxicillin-clavulanate alone does NOT cover atypical pathogens.
3. When NOT to use: ⛔ Do NOT use as monotherapy for severe CAP (CURB-65 ≥3, ICU admission) — requires broader-spectrum IV therapy (piperacillin-tazobactam or ceftriaxone + macrolide/fluoroquinolone per institutional protocol). Do NOT use for suspected atypical pneumonia as monotherapy (no activity against Mycoplasma, Legionella, Chlamydophila). Do NOT use if aspiration pneumonia with anaerobic coverage needed (add metronidazole or use amoxicillin-clavulanate IV which has some anaerobic activity, but metronidazole addition may be required).
4. NLEM India: ✅ Yes.
5. Time to response: Clinical improvement (defervescence, reduced cough, improved oxygenation) expected within 48–72 hours. CRP should decline by >50% at day 3–4 if available. Chest X-ray improvement lags behind clinical improvement by 2–4 weeks — do not repeat X-ray within the first week unless clinically worsening.
6. Treatment failure at 72 hours: Reassess: rule out complications (empyema, lung abscess), drug-resistant organism, atypical pathogen, or non-infectious mimic (malignancy, TB, eosinophilic pneumonia). Obtain sputum culture and sensitivity. Consider broadening coverage: switch to respiratory fluoroquinolone or ceftriaxone ± macrolide.
7. ⚠️ India-specific: Always consider tuberculosis in the differential diagnosis of non-resolving pneumonia, especially if: risk factors present, no response to antibiotics in 2 weeks, cavitary lesion, weight loss, or epidemiological exposure. Obtain sputum for AFB and GeneXpert before labelling as “treatment failure CAP.”
8. Baseline investigations: MANDATORY: Chest X-ray (PA view). Allergy history. RECOMMENDED: SpO₂ (pulse oximetry), CBC, CRP/procalcitonin (if available), renal function (especially elderly, diabetics). Sputum culture before starting antibiotics (if hospitalised). Blood cultures x2 (if hospitalised/severe).
9. Specialist initiation: Not required for outpatient mild CAP — appropriate for primary care. Hospitalised CAP should be managed by physician/internist. ICU-level care for severe CAP.
10. Indian guideline: API Textbook of Medicine; ICMR Antimicrobial Treatment Guidelines 2019; Joint ICS-NCDC Guidelines for CAP.
11. Safety warning: Monitor for Clostridioides difficile-associated diarrhoea (CDAD), especially in hospitalised patients or those with recent antibiotic exposure. New-onset profuse watery or bloody diarrhoea during or after antibiotic course → suspect CDAD → test for C. difficile toxin.
12. Dose adjustment: Renal impairment (see Renal Adjustment). Elderly — dose per renal function; be alert for hepatotoxicity with courses >7 days.

---

Indication 4: ACUTE EXACERBATION OF COPD (AECOPD)

Mandatory Clinical Notes:

1. When to prefer: Antibiotics are indicated in AECOPD only when at least two of three Anthonisen criteria are met: (a) increased dyspnoea, (b) increased sputum volume, © increased sputum purulence — with purulence being the strongest predictor of bacterial infection. Amoxicillin-clavulanate is first-line for moderate-severe AECOPD per GOLD 2024 and API Textbook, particularly in patients with:
2. • FEV1 <50% predicted
   • ≥2 exacerbations/year
   • Comorbidities (diabetes, CHF, renal disease)
3. When NOT to use: Do NOT use antibiotics for mild AECOPD with only increased dyspnoea (without purulent sputum). If sputum is mucoid (white/clear), antibiotics are unlikely to benefit. Do NOT use for stable COPD as prophylaxis (except azithromycin long-term prophylaxis in select cases — different indication entirely).
4. NLEM India: ✅ Yes.
5. Time to response: Improvement in sputum character and dyspnoea within 48–72 hours.
6. Treatment failure: If no improvement at 72 hours, obtain sputum culture. Consider: respiratory fluoroquinolone, or broader gram-negative coverage if Pseudomonas risk factors (frequent exacerbations, recent hospitalisation, structural lung disease, chronic steroid use).
7. Baseline investigations: MANDATORY: Allergy history. SpO₂. RECOMMENDED: Chest X-ray (rule out pneumonia), sputum culture (if hospitalised or frequent exacerbations), ABG (if SpO₂ <92% or severe dyspnoea), CBC, CRP.
8. Specialist initiation: Not required for outpatient management. Pulmonologist involvement for frequent exacerbators or treatment failure.
9. Indian guideline: API Textbook of Medicine (COPD chapter); GOLD 2024 (supportive international reference).
10. Safety warning: ⚠️ In COPD patients on systemic corticosteroids for exacerbation, be alert for oral candidiasis and secondary infections.
11. Dose adjustment: Renal impairment — see Renal Adjustment. Many COPD patients are elderly with declining renal function.

---

Indication 5: URINARY TRACT INFECTIONS (UTI)

5A: Uncomplicated Lower UTI (Acute Cystitis)

Condition-specific notes — Uncomplicated Cystitis:

• ⚠️ Amoxicillin-clavulanate is NOT first-line for uncomplicated cystitis. Preferred first-line agents per ICMR and IDSA guidelines: Nitrofurantoin 100 mg BD × 5 days or Fosfomycin 3 g single dose. Amoxicillin-clavulanate is a reasonable second-line option when first-line agents cannot be used (allergy, contraindication, resistance on C&S) or based on local antibiogram.
• The high resistance rates to amoxicillin (>40% in many Indian centres) are overcome by clavulanate in many — but not all — beta-lactamase-producing uropathogens. Local antibiogram should guide empirical choice.
• Obtain urine culture and sensitivity before prescribing empirically, particularly in India where multi-drug-resistant E. coli and Klebsiella are increasingly prevalent.

5B: Complicated UTI / Acute Pyelonephritis

Condition-specific notes — Complicated UTI / Pyelonephritis:

• Amoxicillin-clavulanate IV is a reasonable empiric option for non-severe pyelonephritis if local susceptibility data supports it. However, in many Indian tertiary centres, ESBL-producing E. coli and Klebsiella prevalence exceeds 50%, making cephalosporins and amoxicillin-clavulanate unreliable as empiric monotherapy for complicated UTIs. Always send urine culture before starting and de-escalate based on sensitivity.
• For severe septic pyelonephritis or urosepsis: prefer piperacillin-tazobactam, ceftriaxone, or carbapenems based on institutional antibiogram. Amoxicillin-clavulanate is not first-line for severe complicated UTI in most Indian tertiary care settings.

Mandatory Clinical Notes (both UTI subtypes):

1. NLEM India: ✅ Yes.
2. Time to response: Uncomplicated cystitis: symptom improvement within 24–48 hours. Pyelonephritis: defervescence within 48–72 hours.
3. Treatment failure: If febrile at 72 hours in pyelonephritis, obtain repeat culture, renal ultrasound (rule out obstruction/abscess). Switch antibiotic based on C&S.
4. Baseline investigations: MANDATORY: Urine routine and culture-sensitivity before starting. Allergy history. RECOMMENDED: Renal function, blood culture if hospitalised. Renal ultrasound if complicated/recurrent UTI.
5. Specialist initiation: Primary care appropriate for uncomplicated cystitis. Pyelonephritis: physician/internist for hospitalised cases; urologist for complicated/recurrent/obstructive UTI.
6. Indian guideline: ICMR Antimicrobial Treatment Guidelines 2019; API Textbook; AIIMS Empiric Antibiotic Guidelines.
7. Dose adjustment: Renal impairment — see Renal Adjustment (critical for UTI patients who may already have impaired renal function).

---

Indication 6: SKIN AND SOFT TISSUE INFECTIONS (SSTI), including BITE WOUNDS

6A: Cellulitis, Wound Infections, Subcutaneous Abscesses (Post-Drainage)

Condition-specific notes — General SSTI:

• Amoxicillin-clavulanate provides coverage against S. aureus (MSSA), Streptococcus pyogenes, anaerobes, and gram-negative organisms commonly involved in polymicrobial soft tissue infections.
• ⛔ Does NOT cover MRSA. If MRSA is suspected (previous MRSA infection, nosocomial wound, high local MRSA prevalence), add or switch to clindamycin, cotrimoxazole, linezolid, or vancomycin per severity.
• For small subcutaneous abscesses: Incision and drainage alone is often sufficient without antibiotics. Antibiotics (including amoxicillin-clavulanate) should be added only if: surrounding cellulitis is significant, systemic signs present, immunocompromised patient, or abscess in high-risk location (face, hand, perineum).

6B: Animal and Human Bite Wounds

Condition-specific notes — Bite Wounds:

• 💡 Amoxicillin + Clavulanate is the FIRST-LINE and DRUG OF CHOICE for animal (dog, cat, monkey) and human bite wound infections/prophylaxis. This is one of the clearest indications for this combination.
• Covers Pasteurella multocida (cat/dog bites), Eikenella corrodens (human bites), oral anaerobes, streptococci, and staphylococci — the typical polymicrobial flora of bite wounds.
• ⚠️ India-specific: Dog bites are extremely common in India. Always concurrently assess and administer anti-rabies prophylaxis (anti-rabies vaccine ± rabies immunoglobulin) per National Rabies Control Programme guidelines. Amoxicillin-clavulanate treats/prevents secondary bacterial infection but has NO activity against rabies virus.
• For penicillin-allergic patients: Use doxycycline + metronidazole (or clindamycin + fluoroquinolone) as alternative.
• High-risk bites warranting prophylaxis: deep puncture wounds (especially cat bites), hand wounds, wounds near joints/tendons/bone, crush injuries, immunocompromised patients, human bites.

Mandatory Clinical Notes (SSTI — both subtypes):

1. NLEM India: ✅ Yes.
2. Time to response: 48–72 hours. Surrounding erythema should stop progressing; pain and swelling should begin to reduce. Mark the extent of cellulitis with ink to track progression.
3. Treatment failure: No improvement at 72 hours → consider MRSA, deeper infection (necrotising fasciitis, osteomyelitis), abscess requiring drainage, or alternative diagnosis. Obtain wound culture. Imaging (ultrasound/MRI) for suspected deep collection.
4. Baseline investigations: MANDATORY: Allergy history. RECOMMENDED: Wound swab for culture (before antibiotics if purulent). Blood glucose (uncontrolled diabetes is a common predisposing factor in Indian patients).
5. Specialist initiation: Primary care appropriate for uncomplicated. Surgical referral for: deep abscesses, bite wounds requiring debridement, suspected necrotising fasciitis, hand infections.
6. Indian guideline: API Textbook; ICMR AMR Treatment Guidelines 2019; National Rabies Control Programme (for bite wound management).
7. Key safety warning: ⚠️ For diabetic foot infections — see separate note below.

---

Indication 7: DENTAL AND PERIODONTAL INFECTIONS

Mandatory Clinical Notes:

1. When to prefer: Amoxicillin + Clavulanate is recommended for dental infections (periapical abscess, acute periodontitis, post-extraction infections) when amoxicillin alone has failed (treatment failure at 48–72 hours) or when infection is moderate-severe with spreading cellulitis. First-line for most dental infections is still amoxicillin alone (500 mg TDS) or metronidazole alone.
2. When NOT to use: Toothache without infection signs (pain alone is not an indication for antibiotics). Minor gingival inflammation.
3. NLEM India: ✅ Yes.
4. Time to response: 48–72 hours. Pain relief and reduction in swelling expected.
5. Treatment failure: ENT/dental surgeon referral for incision and drainage, root canal, or extraction. Empiric switch to clindamycin 300 mg QDS if no improvement.
6. Baseline investigations: Clinical examination. Dental X-ray if periapical pathology suspected.
7. Specialist initiation: Primary care can initiate for uncomplicated dental infections. Dental/maxillofacial surgeon referral for deep space infections (submandibular, parapharyngeal, Ludwig’s angina).
8. Key safety warning: ⛔ Ludwig’s angina (bilateral submandibular space infection with floor-of-mouth swelling) is a dental emergency requiring IV antibiotics and urgent surgical referral — do NOT manage with oral amoxicillin-clavulanate alone.
9. Indian guideline: API Textbook; Indian Dental Association Clinical Guidelines.

---

Indication 8: INTRA-ABDOMINAL INFECTIONS — Mild to Moderate, Community-Acquired

Mandatory Clinical Notes:

1. When to prefer: Amoxicillin-clavulanate IV is appropriate for mild-moderate, community-acquired intra-abdominal infections (acute appendicitis without perforation/abscess, localised peritonitis, uncomplicated biliary infections/cholangitis, intra-abdominal abscess — post-drainage). Provides adequate coverage against enteric gram-negatives, streptococci, and anaerobes (Bacteroides fragilis — though resistance to amoxicillin-clavulanate among B. fragilis is increasing in some Indian centres).
2. When NOT to use: ⛔ NOT adequate for severe/hospital-acquired intra-abdominal infections, tertiary peritonitis, or infections with suspected ESBL-producing organisms (common in Indian hospitals). Use piperacillin-tazobactam, carbapenems, or cephalosporin + metronidazole per institutional protocol.
3. NLEM India: ✅ Yes.
4. Time to response: Improvement within 48–72 hours post-source-control. If no improvement, reassess source control adequacy and consider broader-spectrum therapy.
5. Key note:Source control (surgical drainage, appendectomy, cholecystectomy) is paramount — antibiotics alone without source control are insufficient for most intra-abdominal infections.
6. Baseline investigations: MANDATORY: CBC, renal function, LFTs, blood culture. Imaging (USG/CT abdomen) for localisation. Intra-operative/aspirate culture.
7. Specialist initiation: Surgeon involvement mandatory. Physician/ID specialist for antibiotic decisions in complicated cases.
8. Indian guideline: API Textbook of Medicine; Surgical Infections Society guidelines (adapted for India).

---

Indication 9: GYNAECOLOGICAL AND OBSTETRIC INFECTIONS

Mandatory Clinical Notes:

1. When to prefer: Amoxicillin-clavulanate IV is one component of multi-drug regimens for polymicrobial gynaecological infections. Provides coverage against aerobic and anaerobic organisms.
2. For PID: Usually combined with doxycycline (100 mg BD × 14 days) ± metronidazole (500 mg BD × 14 days). Amoxicillin-clavulanate is not monotherapy for PID.
3. ⚠️ India-specific warning: In obstetric infections, always assess for sepsis (qSOFA/SOFA score). Post-partum sepsis remains a leading cause of maternal mortality in India.
4. NLEM India: ✅ Yes.
5. Specialist initiation: Obstetrician/gynaecologist involvement mandatory.
6. Key safety warning: ⚠️ Avoid amoxicillin-clavulanate for preterm prelabour rupture of membranes (PPROM) prophylaxis — the ORACLE-I trial demonstrated increased risk of neonatal necrotising enterocolitis (NEC) with co-amoxiclav given antenatally for PPROM. Use erythromycin as prophylaxis for PPROM per RCOG/NICE and Indian obstetric practice guidelines.
7. Indian guideline: FOGSI Guidelines; API Textbook (Obstetric Infections); ICMR.

---

Indication 10: BONE AND JOINT INFECTIONS — Oral Step-Down Therapy

Mandatory Clinical Notes:

1. When to prefer: Oral step-down with amoxicillin-clavulanate is appropriate for bone and joint infections caused by susceptible organisms (C&S-proven MSSA, streptococci, susceptible gram-negatives) after initial IV therapy, clinical improvement, and normalisation of inflammatory markers.
2. When NOT to use: Not for MRSA osteomyelitis (use vancomycin/linezolid IV), not for Pseudomonas (use antipseudomonal agents), not as empiric first-line without culture data.
3. Specialist initiation: ⚠️ MANDATORY — orthopaedic surgeon + ID specialist/physician involvement essential. Long-duration oral antibiotic therapy for osteomyelitis must be supervised by specialist.
4. Key evidence: The OVIVA trial (2019) demonstrated non-inferiority of oral step-down antibiotics (including amoxicillin-clavulanate) compared with IV-only therapy for bone and joint infections, supporting early oral switch after initial IV therapy.
5. Baseline investigations: MANDATORY: Bone/joint culture (ideally intraoperative), blood culture, inflammatory markers (CRP, ESR), imaging (X-ray, MRI).
6. Indian guideline: API Textbook; AIIMS Orthopaedic Infection Protocol; OVIVA trial data (supportive international evidence, increasingly adopted in Indian practice).

---

Indication 11: SURGICAL PROPHYLAXIS

• Colorectal surgery / appendicectomy
• Head and neck surgery involving mucosal incision
• Upper GI / biliary surgery (open cholecystectomy, biliary procedures)
• Gynaecological surgery (hysterectomy, especially vaginal)
• Contaminated/dirty traumatic wounds

Mandatory Clinical Notes:

1. When to prefer: Amoxicillin-clavulanate IV provides broad coverage against skin flora, enteric gram-negatives, and anaerobes — making it a versatile single-agent prophylactic choice for many clean-contaminated and contaminated surgeries. Preferred when anaerobic coverage is needed without adding metronidazole.
2. When NOT to use: Clean surgeries where cefazolin alone is standard (cardiac surgery, orthopaedic implant surgery — use cefazolin or cefuroxime per protocol). Not adequate where MRSA prophylaxis is needed (add vancomycin).
3. NLEM India: ✅ Yes.
4. ⚠️ Timing is critical: Administer within 60 minutes before incision. Administering too early (>60 min before) or too late (after incision) significantly reduces prophylactic efficacy. For IV amoxicillin-clavulanate, infuse over 30 minutes — so start infusion ~60 minutes before incision time.
5. Key safety warning: ⛔ Prolonged prophylaxis (>24 hours) does NOT reduce surgical site infection (SSI) rates and increases antimicrobial resistance and Clostridioides difficile risk. This is a common prescribing error in Indian surgical practice — antibiotics are frequently continued for 5–7 days post-surgery without indication.
6. Indian guideline: API Textbook (Surgical Infections chapter); AIIMS Surgical Prophylaxis Protocol; National Centre for Disease Control (NCDC) — Infection Control Guidelines.

---

Secondary Indications — Adults Only (Off-label, if any)

---

Off-Label Indication 1: LOW-RISK FEBRILE NEUTROPENIA — Oral Outpatient Therapy

Status:OFF-LABEL but accepted standard practice in Indian tertiary oncology centres.

• Appropriate ONLY for patients meeting all low-risk criteria: MASCC risk score ≥21, expected neutropenia duration <7 days, no haemodynamic instability, no organ dysfunction, no uncontrolled comorbidity, no IV catheter-related infection, adequate oral intake, reliable follow-up.
• ⚠️ Specialist only — oncologist or haematologist must assess risk stratification before initiating oral therapy. Not for primary care initiation.
• The patient must be able to take oral medications and have reliable access to emergency care if deterioration occurs.
• Evidence basis:Strong — Multiple RCTs (Kern et al., Freifeld et al.) and IDSA/ASCO Febrile Neutropenia Guidelines support this approach. Adopted in Indian oncology practice per AIIMS and TMC (Tata Memorial Centre) protocols.
• ℹ️ Do NOT use amoxicillin-clavulanate as monotherapy — always combine with ciprofloxacin for this indication.
• ℹ️ If patient has received fluoroquinolone prophylaxis, do NOT use this oral regimen (overlapping fluoroquinolone exposure) — admit for IV antibiotics.

---

Off-Label Indication 2: CHRONIC SUPPRESSIVE ORAL ANTIBIOTIC THERAPY FOR PROSTHETIC JOINT INFECTIONS (PJI)

• Used as chronic oral suppressive therapy when prosthetic joint cannot be removed or exchanged (patient unfit for revision surgery, patient declines surgery, or two-stage exchange not feasible) and the organism is susceptible.
• ⚠️ Specialist only — ID specialist + orthopaedic surgeon decision.
• Periodic monitoring of LFTs mandatory (every 3 months) during prolonged courses due to hepatotoxicity risk.
• Evidence basis:Moderate — Observational studies, IDSA PJI Guidelines (2013), expert consensus. Limited Indian-specific data.

---

Off-Label Indication 3: ACTINOMYCOSIS — Oral Step-Down Therapy

• First-line for actinomycosis is IV penicillin G or IV ampicillin for the initial phase. Amoxicillin-clavulanate is used for oral step-down/consolidation.
• Extended courses (total 6–12 months) are standard for thoracic and abdominal actinomycosis.
• ⚠️ Monitor LFTs every 4–6 weeks during prolonged therapy.
• Evidence basis:Weak — case series, expert opinion, textbook recommendations.

---

PAEDIATRIC DOSING (Specialist Only)

---

• Safety monitoring: Monitor for diarrhoea (the most common adverse effect in children, driven largely by the clavulanate component), nappy rash, oral candidiasis, and allergic reactions (rash, urticaria, anaphylaxis). Educate caregivers to seek immediate medical attention for signs of allergic reaction.
• Minimum age: No absolute lower age limit established — used in infants from birth in exceptional circumstances under specialist supervision. Commonly prescribed from ≥3 months of age for standard paediatric indications.
• Minimum weight: Weight-based dosing is the standard. No specific minimum weight threshold, but neonatal/preterm use requires specialist dosing (see below).
• Formulation suitability:
• • Oral suspension (dry syrup) is available and appropriate for children who cannot swallow tablets — widely available in India.
  • Dispersible tablets (228.5 mg DT, 457 mg DT) available for children who can manage dispersible formulations.
  • Film-coated tablets are for children ≥12 years or ≥40 kg who can swallow tablets whole.
• Palatability: Most Indian brands of oral suspension have a fruity or banana flavour and are generally well-accepted. Some children may find the taste bitter or refuse it — can be given with milk or food (does not significantly affect absorption and improves clavulanate absorption). Refrigeration of reconstituted suspension improves palatability.
• Age-specific PK differences: Neonates have prolonged half-life (3–4 hours vs 1–1.3 hours in older children/adults) due to immature renal function. Infants and children have relatively higher renal clearance per kg compared to adults, necessitating weight-based dosing.

---

PAEDIATRIC DOSING REFERENCE TABLE

Maximum paediatric dose (adult ceiling):

• Per dose maximum: 500 mg amoxicillin (q8h regimen) or 875 mg amoxicillin (q12h regimen)
• Per day maximum: 1750 mg amoxicillin/day (BD) or 1500 mg/day (TDS)
• Clavulanate maximum: 10 mg/kg/day or 375 mg/day (whichever is lower)
• Transition to adult dosing: Children ≥12 years of age OR ≥40 kg body weight → use adult dosing.

---

Primary Indications — Paediatric (Approved / Standard in India)

---

Paediatric Indication 1: ACUTE OTITIS MEDIA (AOM)

Clinical Notes:

• First-line for uncomplicated AOM in most children is amoxicillin alone (80–90 mg/kg/day divided q12h or q8h). Amoxicillin-clavulanate is second-line (after amoxicillin failure at 48–72 hours) or first-line in the specific risk factor scenarios listed above.
• IAP (Indian Academy of Pediatrics) Guidelines for AOM recommend high-dose amoxicillin as first-line and amoxicillin-clavulanate as the preferred second-line agent, consistent with AAP guidelines.
• Treatment failure (no improvement at 72 hours on amoxicillin-clavulanate): Consider tympanocentesis (ENT referral), ceftriaxone 50 mg/kg/day IM × 3 days, or clindamycin.
• NLEM India: ✅ Yes.

---

Paediatric Indication 2: ACUTE BACTERIAL SINUSITIS

Clinical Notes:

• Similar approach to AOM: amoxicillin alone is first-line; amoxicillin-clavulanate for treatment failure or high-risk patients.
• In children, diagnosis requires persistence of symptoms ≥10 days without improvement, or severe onset, or worsening after initial improvement.
• NLEM India: ✅ Yes.

---

Paediatric Indication 3: COMMUNITY-ACQUIRED PNEUMONIA (CAP) — Paediatric

Clinical Notes:

• For outpatient paediatric CAP, first-line is amoxicillin alone (50 mg/kg/day) per IAP, WHO, and ICMR guidelines. Amoxicillin-clavulanate is second-line if amoxicillin fails, or first-line in children with: aspiration risk, structural lung disease, or suspected mixed/polymicrobial infection.
• For hospitalised paediatric CAP: IV amoxicillin-clavulanate is a reasonable empiric option, especially if no ICU requirement.
• ⚠️ In children <5 years in India, always consider pulmonary tuberculosis in non-resolving pneumonia.
• IAP Guidelines for Paediatric Pneumonia; WHO Revised Pneumonia Classification (for resource-limited settings).
• NLEM India: ✅ Yes.

---

Paediatric Indication 4: URINARY TRACT INFECTIONS — Paediatric

Clinical Notes:

• Obtain urine culture (clean-catch or catheter specimen) before starting antibiotics.
• ⚠️ In Indian children, ESBL-producing E. coli is increasingly common — local antibiogram should guide empiric choice. Amoxicillin-clavulanate is appropriate only if local susceptibility supports it.
• All children with first febrile UTI should undergo renal ultrasound (RECOMMENDED). DMSA scan and MCU per IAP Paediatric Nephrology guidelines.
• IAP Guidelines for UTI in Children.
• NLEM India: ✅ Yes.

---

Paediatric Indication 5: SKIN AND SOFT TISSUE INFECTIONS, including BITE WOUNDS — Paediatric

Clinical Notes:

• Drug of choice for paediatric bite wound infections/prophylaxis (same rationale as adults).
• ⚠️ India-specific: Dog bites in children are extremely common and often more severe (face/head involvement in young children). Always assess and administer anti-rabies prophylaxis per National Rabies Control Programme guidelines.
• NLEM India: ✅ Yes.

---

Paediatric Indication 6: PERIORBITAL (PRESEPTAL) CELLULITIS — Paediatric

Clinical Notes:

• ⚠️ CRITICAL: Differentiate preseptal (periorbital) cellulitis from orbital cellulitis (ophthalmic emergency). Orbital cellulitis features: proptosis, painful/limited extraocular movements, decreased visual acuity, afferent pupillary defect. Orbital cellulitis requires urgent CT orbit, IV antibiotics, and ophthalmology/ENT/neurosurgery consultation.
• Amoxicillin-clavulanate is appropriate for preseptal cellulitis. For orbital cellulitis, broader IV coverage is needed (ceftriaxone + metronidazole or piperacillin-tazobactam per protocol).
• IAP Guidelines; AIIMS Paediatric Ophthalmology Protocol.
• NLEM India: ✅ Yes.

---

Neonatal Dosing

Critical Neonatal Notes:

• ⛔ Amoxicillin-clavulanate is NOT first-line for neonatal sepsis. Standard empiric therapy for early-onset neonatal sepsis (EONS) in India is Ampicillin + Gentamicin per NNF (National Neonatology Forum) / AIIMS Neonatal Protocol.
• Use of amoxicillin-clavulanate in neonates is reserved for specific targeted therapy based on culture sensitivity under specialist guidance.
• ⛔ Avoid in preterm neonates if possible — the ORACLE-I trial (Kenyon et al., Lancet 2001) demonstrated an increased risk of neonatal necrotising enterocolitis (NEC) with antenatal co-amoxiclav exposure. While this was antenatal maternal exposure, caution extends to direct neonatal administration in preterm infants.
• Immature renal function in neonates significantly prolongs half-life — extended dosing interval is essential.

---

Secondary Indications — Paediatric (Off-label, if any)

Off-Label Paediatric Indication 1: PROPHYLAXIS OF RECURRENT AOM

Clinical Notes:

• Considered only for children with ≥3 AOM episodes in 6 months or ≥4 in 12 months, after ENT assessment (tympanostomy tubes should be considered first).
• ⚠️ IAP and most current guidelines discourage antibiotic prophylaxis for recurrent AOM due to AMR risk and limited benefit demonstrated in recent evidence.
• Evidence basis:Weak — older studies showed modest benefit; current IAP and AAP guidelines de-emphasise prophylactic antibiotics in favour of tympanostomy tubes for recurrent AOM.
• Clearly marked OFF-LABEL.
• Not recommended below 6 months of age for prophylaxis.

---

Off-Label Paediatric Indication 2: PROTRACTED BACTERIAL BRONCHITIS (PBB)

Clinical Notes:

• PBB is caused by persistent lower airway bacterial infection, most commonly non-typeable Haemophilus influenzae (NTHi — frequently beta-lactamase producing), Streptococcus pneumoniae, and Moraxella catarrhalis. Amoxicillin-clavulanate is preferred over amoxicillin alone because NTHi and M. catarrhalis are frequently beta-lactamase producers.
• 💡 Clinical Pearl — India-specific: Chronic wet cough in Indian children is very commonly misdiagnosed as “asthma” or “allergic bronchitis” and treated with prolonged inhaled corticosteroids, bronchodilators, or antihistamines — all of which are ineffective for PBB. If a child has chronic wet cough without wheeze, exercise limitation, or atopy features, consider PBB and trial amoxicillin-clavulanate before labelling as asthma. Resolution of cough with antibiotics confirms the diagnosis retrospectively.
• ⚠️ Always rule out tuberculosis before labelling as PBB in Indian children — chest X-ray, Mantoux test, and GeneXpert sputum/gastric aspirate where available. A non-resolving chronic cough in an Indian child warrants TB evaluation as a priority.
• ⚠️ If PBB recurs ≥3 times/year or fails to respond to 4–6 weeks of therapy, investigate for underlying causes: bronchiectasis (HRCT chest), immunodeficiency (immunoglobulin levels), cystic fibrosis (sweat chloride test — rare in India but not absent), primary ciliary dyskinesia.
• Evidence basis:Strong — Multiple paediatric RCTs and meta-analyses (Marchant et al., Chang et al.) support antibiotic therapy for PBB. European Respiratory Society (ERS) and Thoracic Society of Australia and New Zealand (TSANZ) guidelines recommend amoxicillin-clavulanate as first-line. Adopted in Indian paediatric pulmonology practice (IAP Respiratory Chapter consensus).
• Specialist involvement: Initial diagnosis and management may be by a general paediatrician. Refer to paediatric pulmonologist if: recurrent PBB, treatment failure, suspected underlying bronchiectasis.

---

Off-Label Paediatric Indication 3: CHRONIC SUPPURATIVE OTITIS MEDIA (CSOM) — Oral Therapy

Clinical Notes:

• CSOM is defined as chronic ear discharge through a tympanic membrane perforation for >2 weeks (some definitions: >6 weeks). It is extremely common in Indian children, particularly in underserved communities — prevalence in some studies exceeds 5% of school-age children.
• First-line for CSOM is topical ear drops (ciprofloxacin ear drops or ciprofloxacin + dexamethasone ear drops) with aural toilet (dry mopping). Systemic oral antibiotics are second-line, used when:
• • Topical therapy alone fails after 2–4 weeks
  • Acute exacerbation with systemic symptoms (fever, increasing pain)
  • Suspected complications (mastoiditis, intracranial extension)
  • Bilateral CSOM with heavy discharge
• Amoxicillin-clavulanate provides coverage against the typical CSOM pathogens: Pseudomonas aeruginosa (partially — limited activity), S. aureus (MSSA), Proteus spp., H. influenzae, anaerobes.
• ⚠️ Limitation: Amoxicillin-clavulanate has inadequate anti-pseudomonal activity. If Pseudomonas aeruginosa is isolated on culture, use oral ciprofloxacin (off-label in children but commonly used for CSOM) or appropriate topical therapy. Ear swab culture and sensitivity is recommended before prescribing systemic antibiotics for CSOM.
• Evidence basis:Moderate — Cochrane reviews support systemic antibiotics for CSOM but with limited evidence on which specific oral antibiotic is best. IAP ENT Guidelines and WHO Primary Ear and Hearing Care Training Resource recommend topical therapy as first-line with systemic antibiotics as adjunctive.
• Specialist involvement: ENT referral recommended for all CSOM cases, especially if: complications suspected, cholesteatoma, hearing loss, or failure of conservative management (surgical intervention — mastoidectomy/tympanoplasty may be needed).
• Indian guideline: IAP ENT Guidelines; WHO Primary Ear and Hearing Care Guidelines; API Textbook.

---

Off-Label Paediatric Indication 4: UTI PROPHYLAXIS IN VESICOURETERAL REFLUX (VUR) — Select Cases

Clinical Notes:

• ⚠️ Amoxicillin-clavulanate is NOT the preferred agent for UTI prophylaxis in children with VUR. First-line prophylactic agents per IAP Paediatric Nephrology Guidelines:
• • Infants (<2 months): Amoxicillin alone or cephalexin
  • Older children: Cotrimoxazole (trimethoprim-sulfamethoxazole) or nitrofurantoin
• Amoxicillin-clavulanate may be considered as an alternative when first-line prophylactic agents are not tolerated (sulfa allergy for cotrimoxazole, GI intolerance for nitrofurantoin) or when breakthrough UTIs on standard prophylaxis suggest resistant organisms.
• The addition of clavulanate theoretically provides broader coverage against beta-lactamase-producing uropathogens, but evidence for superiority over amoxicillin alone in prophylaxis is limited.
• Continuous antibiotic prophylaxis (CAP) for VUR is itself debated. The RIVUR trial (2014) showed modest benefit of cotrimoxazole prophylaxis in preventing recurrent UTI in children with VUR grades I–IV, but significant resistance emergence. Current Indian practice (IAP) generally recommends prophylaxis for:
• • High-grade VUR (Grade III–V)
  • Recurrent febrile UTIs
  • Infants with VUR
  • Post-operative prophylaxis after ureteral reimplantation
• Evidence basis:Weak — No RCTs specifically studying amoxicillin-clavulanate for VUR prophylaxis. Expert opinion and extrapolation from general UTI prophylaxis data.
• Specialist only: ⚠️ Paediatric nephrologist or urologist must supervise. Not for primary care initiation.
• Monitoring: Periodic urine cultures (every 3–6 months), renal function, renal ultrasound, DMSA scan as per IAP protocol.

---

Off-Label Paediatric Indication 5: RETROPHARYNGEAL / PARAPHARYNGEAL ABSCESS — Oral Step-Down

Clinical Notes:

• Retropharyngeal and parapharyngeal abscesses are surgical emergencies in children — most common in children <5 years. The primary management is surgical drainage (transoral or transcervical) + IV antibiotics.
• Amoxicillin-clavulanate IV provides coverage against the typical polymicrobial flora: Group A Streptococcus, S. aureus (MSSA), oral anaerobes. Often combined with metronidazole for enhanced anaerobic coverage, or clindamycin may be used as an alternative/addition.
• ⛔ If MRSA is suspected (previous MRSA, nosocomial, high local prevalence): add clindamycin or vancomycin.
• ⚠️ Life-threatening complications include airway obstruction, mediastinitis, aspiration pneumonia, jugular vein thrombosis (Lemierre syndrome), and carotid artery erosion. ENT/paediatric surgery and anaesthesia involvement are essential.
• Oral step-down with amoxicillin-clavulanate after adequate surgical and IV management.
• Evidence basis:Moderate — Case series, paediatric ENT consensus; no RCTs for specific antibiotic choice. Standard practice in paediatric otolaryngology.
• Specialist only: ⚠️ MANDATORY — ENT surgeon + paediatrician.
• Indian guideline: IAP Infectious Disease Guidelines; AIIMS Paediatric ENT Protocol.

---

Off-Label Paediatric Indication 6: ACUTE BACTERIAL LYMPHADENITIS (Cervical) — When First-Line Fails

Clinical Notes:

• Acute unilateral cervical lymphadenitis in children is most commonly caused by S. aureus (MSSA) and Streptococcus pyogenes. First-line treatment: cephalexin (or flucloxacillin/cloxacillin in Indian practice) OR clindamycin if MRSA suspected.
• Amoxicillin-clavulanate is a second-line alternative when:
• • First-line cephalexin/cloxacillin has failed after 48–72 hours
  • Dental origin suspected (need for anaerobic coverage)
  • Mixed aerobic-anaerobic infection suspected
  • Cat-scratch disease (Bartonella henselae) — amoxicillin-clavulanate is not first-line (azithromycin preferred), but historically used
• ⚠️ India-specific: Always consider tuberculous lymphadenitis (scrofula) in the differential diagnosis of cervical lymphadenopathy in Indian children, especially if: subacute/chronic presentation, matted nodes, constitutional symptoms, TB contact. Obtain FNAC + GeneXpert before labelling as bacterial lymphadenitis.
• Evidence basis:Weak — Expert opinion, textbook recommendations, extrapolation from SSTI guidelines.
• Specialist involvement: General paediatrician can manage. Refer to paediatric surgeon if: abscess formation requiring I&D, no response to antibiotics, or suspicion of atypical mycobacterial lymphadenitis.

---

Summary — Total Secondary Paediatric Indications: 6

---

MISSED DOSE / DELAYED DOSE GUIDANCE

For TDS (Every 8 Hour) Dosing:

• If remembered within 4 hours of the scheduled time: Take the missed dose immediately. Then resume the regular 8-hourly schedule from that point.
• If more than 4 hours late (i.e., the next dose is due within 4 hours): Skip the missed dose entirely. Take the next dose at its scheduled time. Do NOT double the dose.

For BD (Every 12 Hour) Dosing:

• If remembered within 6 hours of the scheduled time: Take the missed dose immediately. Then resume the regular 12-hourly schedule.
• If more than 6 hours late (i.e., the next dose is due within 6 hours): Skip the missed dose entirely. Take the next dose at its scheduled time. Do NOT double the dose.

For IV Dosing (Hospital Setting):

• IV doses are administered by nursing staff on a fixed schedule. If a dose is delayed (e.g., due to procedure, NPO status, line issues), administer as soon as possible and re-space subsequent doses to maintain the q6h or q8h interval. Document the delay and the rescheduled times.
• ⚠️ For critically ill / septic patients: even a single missed IV antibiotic dose can be clinically significant. Prioritise timely administration. If dose is delayed >2 hours, inform the treating physician for reassessment of the schedule.

Prolonged Non-Adherence / Drug Holiday Guidance:

• Amoxicillin-clavulanate is used as a finite-duration antibiotic course, not as chronic indefinite therapy (except in rare scenarios such as chronic suppressive therapy for prosthetic joint infections).
• If 2 or more consecutive doses are missed in a standard treatment course:
• • The antibiotic may have become sub-therapeutic, allowing bacterial regrowth and potential resistance emergence.
  • Resume at the full dose immediately — no re-titration is required.
  • Extend the total duration of therapy by the number of days of missed doses to complete the intended total course.
  • If the infection was clinically improving before the doses were missed, monitor closely for recurrence.
  • If the infection was not yet controlled, reassess the patient clinically (examine, consider repeat cultures) before simply resuming.
• No withdrawal syndrome or rebound effect with abrupt discontinuation.
• For chronic suppressive therapy (prosthetic joint infections — off-label): if multiple doses are missed, resume at the previous dose without re-titration, but consult the supervising specialist if adherence is poor, as subtherapeutic levels may promote resistance in the biofilm organism.

Counselling Point for Caregivers (Paediatric / Elderly):

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

A. ORAL FORMULATIONS — Administration Notes

Film-Coated Tablets (375 mg, 625 mg, 1000 mg):

• Swallow whole with a full glass of water.
• ⛔ Do NOT crush, chew, or split film-coated tablets. The film coating protects against gastric degradation and ensures appropriate release. Crushing alters the ratio delivery and may cause GI irritation.
• Take at the start of a meal — this optimises clavulanate absorption and significantly reduces nausea and GI adverse effects. This is one of the most important administration instructions for this drug.
• If the patient cannot swallow tablets (elderly, dysphagia), switch to oral suspension or dispersible tablet formulation.
• Enteral tube compatibility: Film-coated tablets are NOT suitable for enteral tube administration. Use the oral suspension or disperse a dispersible tablet in 10–15 mL water, flush tube before and after, and administer promptly.

Dispersible Tablets (228.5 mg DT, 457 mg DT):

• Disperse in approximately 10–15 mL of clean drinking water.
• Stir until fully dispersed (usually within 1–2 minutes).
• Drink immediately after dispersing — do not allow to stand for prolonged periods.
• May also be chewed and swallowed with water.
• Suitable for children ≥6 years who can manage this dosage form, or adults with swallowing difficulty.

Dry Syrup / Oral Suspension (Powder for Reconstitution):

---

B. INTRAVENOUS FORMULATIONS — Reconstitution & Administration

Reconstitution of IV Vials

Further Dilution for IV Infusion

Rate of Administration

• Dose = 30 mg/kg × 12 kg = 360 mg amoxicillin per dose
• Using 600 mg vial (500 mg amoxicillin + 100 mg clavulanate) reconstituted in 10 mL → concentration = 50 mg/mL amoxicillin
• Volume to draw = 360 mg ÷ 50 mg/mL = 7.2 mL
• Dilute in 50 mL Normal Saline; infuse over 30 minutes.
• Or: administer 7.2 mL as slow IV injection over 3–4 minutes.

• Extravasation risk: Low — amoxicillin-clavulanate is not a vesicant. If extravasation occurs, it may cause mild local irritation. Apply warm compress; no specific antidote required. Monitor site.
• Phlebitis/thrombophlebitis: Common with peripheral IV administration, especially if infusion is prolonged or concentration is high. Rotate IV sites every 48–72 hours. Consider central line if prolonged IV therapy anticipated.
• Flush line: Flush IV line with 10–20 mL Normal Saline before and after administration, especially if other drugs are being infused.
• IM injection: ⛔ NOT recommended for amoxicillin-clavulanate due to pain at injection site and unpredictable clavulanate absorption.
• Filter requirements: Standard IV set; no special in-line filter required.

• Before reconstitution (dry powder — vials, dry syrup bottles): Store below 25°C in a cool, dry place. No refrigeration required for unopened dry powder. Protect from moisture.
• After reconstitution (oral suspension): Refrigerate (2–8°C) — strongly recommended in Indian climate. If refrigeration unavailable, use within 5 days and store in coolest available location.
• After reconstitution (IV vials): Use immediately or within specified stability window (see above). Do NOT refrigerate IV solution for later use beyond 8 hours.
• ℹ️ Indian context: In rural PHCs and CHCs without reliable refrigeration, dry syrup powder is stable pre-reconstitution. Reconstitute only at the time of dispensing and counsel the family to refrigerate or keep in the coolest part of the house (clay pot cooling, earthen pot method). If ambient temperature consistently exceeds 35°C and no cooling is available, consider using dispersible tablet formulations instead (stable as dry tablets, dissolved fresh for each dose).

---

RENAL ADJUSTMENT

Adult Renal Dosing Adjustment Table

Paediatric Renal Dosing Adjustment

• ARC is defined as CrCl >130 mL/min (measured by 8- or 24-hour urine collection, or estimated in young patients without CKD).
• Common in: young adults (18–50 years), polytrauma, burns, sepsis without organ failure, neurosurgical patients.
• In ARC, amoxicillin clearance is significantly increased → subtherapeutic serum levels with standard dosing → risk of treatment failure, especially for organisms with higher MICs.
• Action: Consider increasing dosing frequency (e.g., q6h instead of q8h for IV amoxicillin-clavulanate) OR using prolonged/extended infusions (each dose infused over 2–4 hours instead of 30 minutes to maximise %fT > MIC).
• ℹ️ Extended infusion dosing for amoxicillin-clavulanate in ARC is an evolving practice — consult ICU pharmacist or ID specialist. Some Indian tertiary ICUs (AIIMS, CMC Vellore) have adopted this approach for beta-lactam optimisation.

• High-dose amoxicillin in patients with reduced renal clearance can cause crystalluria (amoxicillin crystals precipitating in renal tubules), potentially leading to acute kidney injury.
• Prevention: Ensure adequate hydration (maintain good urine output >0.5 mL/kg/hr in adults). Avoid dehydration. Alkalinising urine is NOT specifically recommended for amoxicillin (unlike sulfonamides), but adequate fluid intake is important.
• If crystalluria occurs (haematuria, flank pain, rising creatinine): discontinue drug, hydrate aggressively, consider alternative antibiotic.

---

HEPATIC ADJUSTMENT

• Amoxicillin undergoes minimal hepatic metabolism (~10%) and is primarily renally cleared. Hepatic impairment has minimal effect on amoxicillin pharmacokinetics.
• Clavulanic acid is extensively hepatically metabolised (hydrolysis and β-oxidation). Hepatic impairment can reduce clavulanate clearance and potentially increase exposure, but the clinical significance of clavulanate accumulation is primarily limited to increased GI side effects.
• The primary hepatic concern with amoxicillin-clavulanate is not altered pharmacokinetics but rather the drug’s own hepatotoxicity potential — it is a well-recognised cause of drug-induced liver injury (DILI), specifically cholestatic hepatitis.

---

CONTRAINDICATIONS

⛔ Absolute contraindications — the drug must NEVER be used:

---

• Rationale: Risk of immediate (IgE-mediated) anaphylaxis (Type I hypersensitivity) — potentially fatal within minutes. Also includes history of angioedema or severe urticaria with any penicillin.
• Allergy cross-reactivity:
• • Other penicillins (ampicillin, piperacillin, flucloxacillin, benzylpenicillin): Very high cross-reactivity (~100% structural similarity at the core beta-lactam + thiazolidine ring). ⛔ Do NOT use ANY penicillin if true penicillin allergy is confirmed.
  • Cephalosporins: Cross-reactivity rate is ~1–2% (previously overestimated at 10%). The risk is primarily with first-generation cephalosporins (cephalexin, cefazolin) and those sharing similar R1 side chains with the offending penicillin (e.g., cefadroxil cross-reacts with amoxicillin due to identical R1 side chain). Second, third, and fourth-generation cephalosporins have lower cross-reactivity risk. Approach: If penicillin allergy was a mild non-IgE reaction (delayed rash), cephalosporins may be used with caution. If penicillin allergy was anaphylaxis or severe immediate reaction, avoid first-generation cephalosporins and cefadroxil; third/fourth-generation cephalosporins may be used with caution under observation. Skin testing is the definitive way to assess cross-reactivity risk if available.
  • Carbapenems (meropenem, imipenem, ertapenem): Cross-reactivity rate is <1%. Despite sharing the beta-lactam ring, the side chain structures are sufficiently different. Carbapenems may be used in penicillin-allergic patients with caution and monitoring in most cases (unless the allergy was severe anaphylaxis, in which case skin testing before use is ideal if available).
  • Monobactams (aztreonam): No cross-reactivity with penicillins. Can be used safely in penicillin-allergic patients.
• 💡 Clinical Pearl: Up to 80–90% of patients who report “penicillin allergy” are NOT truly allergic when tested by skin testing or oral challenge. Many had childhood rashes (possibly viral exanthems during infections) misattributed to penicillin. If the “allergy” history is vague or remote, consider referral for penicillin allergy de-labelling (skin testing + graded oral challenge) — this can safely restore access to penicillins and avoid unnecessary use of broader-spectrum or more expensive alternatives. Penicillin allergy de-labelling is increasingly practised in Indian tertiary centres.

---

• Rationale: Documented risk of recurrence on re-exposure, potentially more severe. The hepatotoxicity is considered an immunoallergic/idiosyncratic reaction to clavulanate.
• ℹ️ Amoxicillin alone may be used cautiously in such patients (as clavulanate is the implicated component), but only with informed consent and close LFT monitoring.

---

• Rationale: Amoxicillin (and other antibiotics active against Salmonella Typhi) can inactivate the live attenuated oral typhoid vaccine strain, rendering vaccination ineffective. ⛔ Do NOT co-administer. Complete the antibiotic course and wait ≥3 days (preferably 7 days) before administering the oral typhoid vaccine. Injectable typhoid vaccines (Vi polysaccharide, conjugate vaccines) are not affected.

---

• Rationale: Shared beta-lactam ring structure creates risk of cross-reactive anaphylaxis. While cross-reactivity rates are lower than historically believed (see above), anaphylaxis is a life-threatening event and the risk is not acceptable without formal allergy evaluation.

---

CAUTIONS

---

⚠️ High-Priority Cautions

• Amoxicillin-clavulanate, like all broad-spectrum antibiotics, disrupts colonic flora and increases CDI risk. Patients with prior CDI are at significantly higher risk of recurrence.
• Monitoring: Instruct patient/caregiver to report new-onset watery diarrhoea (≥3 loose stools/day), especially if bloody or accompanied by fever/abdominal pain. If CDI suspected: test for C. difficile toxin (GDH antigen + toxin assay or NAAT/GeneXpert C. diff). Stop amoxicillin-clavulanate and start specific CDI treatment (oral vancomycin or fidaxomicin).
• Action: Use amoxicillin-clavulanate only if clearly indicated. Consider alternative antibiotics with lower CDI risk (e.g., amoxicillin alone if clavulanate not essential). Keep duration as short as possible.

---

• Aminopenicillins (amoxicillin, ampicillin) cause a characteristic diffuse maculopapular rash in 70–100% of patients with acute EBV mononucleosis. This is NOT a true IgE-mediated penicillin allergy — it is a virus-drug interaction phenomenon. However, it is clinically indistinguishable from a drug allergy rash and may lead to mislabelling of penicillin allergy.
• Action: ⛔ Avoid amoxicillin-clavulanate if infectious mononucleosis is suspected or confirmed (sore throat with lymphadenopathy, hepatosplenomegaly, atypical lymphocytes, positive heterophile antibody/Monospot). If a patient with EBV develops a rash on amoxicillin, this does NOT necessarily indicate true penicillin allergy — document clearly and consider future allergy testing to avoid permanent mislabelling.
• ⚠️ India-specific: This scenario is common in young adults presenting with “tonsillitis” treated empirically with amoxicillin — the rash then leads to a lifelong “penicillin allergy” label. Clinicians should maintain a high index of suspicion for EBV before prescribing aminopenicillins for pharyngitis.

---

• Both components accumulate. Risk of neurotoxicity (seizures — rare but serious, especially at very high amoxicillin levels), crystalluria, and increased GI adverse effects from clavulanate accumulation.
• Monitoring: Renal function (serum creatinine, electrolytes) at baseline and during therapy if prolonged. Ensure adequate hydration.
• Action: Dose adjustment mandatory — see Renal Adjustment section. Avoid 875/125 mg tablet.

---

• High-dose amoxicillin (especially in renal impairment) can lower the seizure threshold and rarely cause myoclonic seizures. Risk is dose-dependent and primarily seen with very high IV doses or in renal failure.
• Action: Use standard doses with caution. Ensure renal dose adjustment if applicable. Monitor for any change in seizure frequency or new neurological symptoms.

---

• Amoxicillin-clavulanate can increase INR and risk of bleeding in patients on warfarin by disrupting gut flora (reducing vitamin K-producing bacteria) and potentially by a direct pharmacodynamic interaction.
• Monitoring: Check INR within 3–5 days of starting amoxicillin-clavulanate. Repeat at course completion. Adjust warfarin dose if INR rises above target.
• Action: See Drug Interactions section.

---

• Risk of hepatotoxicity (cholestatic jaundice) increases with duration. Risk of superinfection (oral/vaginal candidiasis, CDI) also increases.
• Monitoring: LFTs at baseline and every 1–2 weeks if therapy extends beyond 14 days. Clinical monitoring for jaundice, pruritus.
• Action: Always use the shortest effective duration. Document the clinical rationale if extending beyond 14 days.

---

• ⛔ Near-absolute contraindication in this specific clinical context — the ORACLE-I trial (Kenyon et al., 2001, 2008 follow-up) demonstrated a statistically significant increase in neonatal necrotising enterocolitis (NEC) and a possible increase in cerebral palsy with antenatal co-amoxiclav for PPROM.
• Action: Do NOT use amoxicillin-clavulanate for PPROM prophylaxis. Use erythromycin as the standard antibiotic prophylaxis for PPROM per RCOG, NICE, FOGSI guidelines.
• ℹ️ This caution is specific to PPROM. Amoxicillin-clavulanate may be used in pregnancy for other indications where it is the appropriate antibiotic choice (see Pregnancy section).

---

Standard Cautions

• Exercise caution in patients with pre-existing liver disease, particularly cholestatic conditions. See Hepatic Adjustment section for details.

---

• Antibiotics may exacerbate symptoms of inflammatory bowel disease or cause antibiotic-associated colitis. Monitor bowel symptoms.

---

• ℹ️ Oral suspensions and some dispersible tablets contain sucrose or other sugars. This contributes a small caloric load per dose that is unlikely to be clinically significant for glycaemic control in most patients, but should be noted for patients on strict carbohydrate-controlled diets.
• ℹ️ Urine glucose testing interference: Amoxicillin can cause false-positive urine glucose tests when using copper-reduction methods (e.g., Benedict’s test, Clinitest). Enzymatic glucose tests (glucose oxidase method — e.g., Diastix, glucometer strips for blood glucose) are not affected. Counsel diabetic patients and hospital laboratory staff.

---

• Some formulations (especially chewable tablets and flavoured suspensions) may contain aspartame (a phenylalanine source). Check specific product labelling before prescribing to patients with PKU. Most Indian tablet formulations do not contain aspartame. Aspartame content, if present, is usually listed on the label.

---

• Each 1.2 g IV vial contains approximately 65 mg sodium (approximately 2.8 mEq). For patients on sodium-restricted diets (heart failure, cirrhosis with ascites, hypertension), be aware of the cumulative sodium load — at q8h dosing, this is approximately 8.4 mEq sodium per day from the drug alone. Unlikely to be clinically significant for most patients, but noteworthy in severe fluid-restricted patients receiving multiple IV drugs.

---

• Prolonged or repeated antibiotic courses can lead to overgrowth of non-susceptible organisms, including oral candidiasis (common in children, elderly, immunocompromised, inhaled corticosteroid users) and vaginal candidiasis (common in women). Monitor for these and treat if they occur.

---

• False-positive urine glucose: As noted above (copper-reduction methods).
• False-positive direct Coombs test: Amoxicillin can cause positive direct antiglobulin test (DAT/Coombs test), which can interfere with crossmatching for blood transfusion. Clinically significant haemolytic anaemia is very rare, but the positive Coombs test may complicate transfusion medicine evaluations.
• Interference with urinary protein estimation: High-dose amoxicillin may interfere with some protein assays.

---

PREGNANCY

---

Trimester-Specific Risk Assessment

Preferred Alternatives in Indian Obstetric Practice

Monitoring During Pregnancy

• Mother: Standard adverse effect monitoring. LFTs if course >7 days (pregnancy itself can alter LFTs — interpret in context). Monitor for vaginal candidiasis (increased risk in pregnancy + antibiotics).
• Fetus/Neonate: No specific fetal monitoring required for standard courses. If used near delivery, observe neonate for oral candidiasis, loose stools, and any signs of sensitisation (rare).

Pre-Conception Counselling

• Not applicable — amoxicillin-clavulanate is used as short-course therapy, not chronic medication. No pre-conception washout period required.
• No requirement for contraception during use.
• No pregnancy prevention programme applicable.

Pregnancy Registry

• No specific pregnancy exposure registry exists for amoxicillin-clavulanate in India. If adverse pregnancy outcomes are suspected to be drug-related, report through the PvPI (Pharmacovigilance Programme of India) ADR reporting system.

Fertility Effects

---

LACTATION

---

Overall Compatibility

• Loose stools or diarrhoea (most common — usually mild)
• Nappy/diaper rash (secondary to loose stools)
• Oral thrush (white patches in mouth) — treat with oral nystatin drops if it occurs
• Skin rash or allergic reaction (very rare — if noticed, stop maternal antibiotic and seek medical attention)
• Feeding difficulties, irritability, or excessive drowsiness (very rare — seek medical attention)

• ℹ️ Optional timing strategy: If concerned about minimising infant exposure, take the dose immediately after completing a breastfeed and before the longest anticipated interval between feeds (e.g., before the night-time sleep stretch). This allows serum and milk levels to decline before the next feed. However, this is not mandatory given the very low RID — convenience and adherence take priority.

• Amoxicillin alone — equally compatible with breastfeeding, slightly lower risk of infant GI disturbance (less effect on gut flora without clavulanate)
• Cephalexin — compatible with breastfeeding
• Erythromycin — compatible (but more maternal GI side effects)

---

ELDERLY

---

Beers Criteria / STOPP-START Relevance

• Review and stop if no longer indicated: In hospitalised elderly patients, IV amoxicillin-clavulanate is sometimes continued beyond the point of clinical necessity (especially post-surgical prophylaxis extended well beyond 24 hours). Actively review and stop antibiotics as soon as the clinical indication is fulfilled. Unnecessary prolongation increases CDI risk, hepatotoxicity risk, and antimicrobial resistance.
• Oral step-down from IV: In elderly hospitalised patients, early switch from IV to oral (within 48–72 hours of clinical improvement and oral tolerance) reduces line-related complications and hospital stay without compromising outcomes.

---

MAJOR DRUG INTERACTIONS

---

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

SERIOUS ADVERSE EFFECTS

---

• 🔴 Skin rash with blisters, peeling, or sores in the mouth/eyes/genitals → possible SJS/TEN
• 🔴 Swelling of face, lips, tongue, or throat; difficulty breathing → possible anaphylaxis/angioedema
• 🔴 Yellow eyes/skin, dark urine, pale stools, persistent nausea, itching → possible liver injury
• 🔴 Severe watery or bloody diarrhoea with fever and abdominal cramps → possible CDI
• 🔴 Unusual bleeding or bruising (especially if on warfarin) → possible anticoagulant interaction
• 🔴 Reduced urine output, blood in urine, flank pain → possible kidney injury
• 🔴 Muscle twitching, jerking, or seizures → possible neurotoxicity

---

MONITORING REQUIREMENTS

---

---

---

• Critically ill patients with augmented renal clearance (ARC) or significantly altered Vd (sepsis, burns, major surgery) — measuring serum amoxicillin levels can guide dose optimisation for target attainment (%fT > MIC). This is an evolving practice limited to select Indian tertiary ICUs (e.g., AIIMS, CMC Vellore, PGIMER).
• Patients with severe renal impairment on modified dosing — to confirm adequate but non-toxic levels.
• Target levels (when measured): No universally established therapeutic range. General guidance: aim for free drug concentration above the organism’s MIC for at least 40–50% of the dosing interval (for serious infections, aim for 100% fT > MIC). Typical susceptibility breakpoint MICs for common organisms: ≤8 mg/L (amoxicillin-clavulanate, CLSI).

• For standard short courses (5–14 days) in otherwise healthy patients: no ongoing monitoring needed after course completion, unless symptoms of hepatotoxicity develop post-course (which can occur up to 6–8 weeks later — counsel patient).
• For prolonged courses: continue monitoring for 4–8 weeks after completing therapy (to capture delayed-onset hepatotoxicity).

---

PATIENT COUNSELLING

---

---

---

• Tablets: Swallow the tablet whole with a full glass of water. Do NOT crush, break, or chew it.
• Liquid medicine (syrup — for children): Shake the bottle well before each use. Use the measuring cup or syringe that comes with the medicine — do NOT use a household spoon. After mixing with water, keep the bottle in the refrigerator.
• Dispersible tablets: Drop the tablet in a small amount (1–2 tablespoons) of clean water, wait until it dissolves completely, stir, and drink it all immediately. You can also chew it and wash it down with water.
• ⚠️ IMPORTANT — Take with food: Always take this medicine at the START of a meal. This helps your stomach handle the medicine better and reduces the chance of feeling sick or getting loose motions.
• Take doses at equal time gaps (every 8 hours for three-times-a-day dosing, or every 12 hours for twice-a-day dosing). Setting an alarm on your phone can help remember.

---

---

• Loose motions (diarrhoea) — this is the most common side effect. It happens because the medicine also affects the normal good bacteria in your stomach. Eat curd (dahi/yoghurt) to help. Drink plenty of water and ORS if needed. If the loose motions are very severe, bloody, or don’t stop, contact your doctor.
• Feeling sick (nausea) or stomach upset — taking the medicine with food helps a lot.
• Vomiting — if you vomit within 30 minutes of taking the medicine, take another dose. If vomiting continues, contact your doctor.
• Mild skin rash — inform your doctor, but don’t stop the medicine without asking first.
• White patches in the mouth (oral thrush) or vaginal itching/discharge — this can happen because the antibiotic disturbs the normal germs in your body. Tell your doctor — simple treatment is available."

---

• Skin rash with blisters, peeling skin, or sores in the mouth, eyes, or private parts — this can be a dangerous reaction
• Swelling of face, lips, tongue, or throat; difficulty breathing or swallowing — this may be a severe allergic reaction
• Yellow colour in your eyes or skin, very dark urine (like tea), clay-coloured/pale stools, or severe itching — this may mean your liver is affected
• Very severe watery or bloody diarrhoea with stomach cramps and fever — this may be a serious bowel infection caused by the antibiotic
• Unusual bruising or bleeding — especially if you are taking blood-thinning medicines
• Very little or no urine, blood in urine, or back pain — may indicate kidney problems
• Fits (seizures) or uncontrollable muscle twitching — very rare but serious"

---

• Alcohol: There is no absolute contraindication, but alcohol can worsen stomach upset and nausea. It is best to avoid or minimise alcohol during the antibiotic course. Alcohol does NOT “cancel out” the antibiotic, but it can make side effects worse.
• Self-stopping: Do NOT stop the medicine early just because you feel better — the infection may come back and the germs may become resistant.
• Sharing medicine: Do NOT share your medicine with anyone else, even if they seem to have the same illness.
• Self-prescribing: Do NOT keep leftover antibiotics for future use or take antibiotics without a doctor’s prescription.

---

• Tablets: Keep in a cool, dry place below 25°C. Keep in the original blister pack. Protect from moisture. Do NOT store in the bathroom.
• Liquid/syrup (after mixing with water): Keep in the refrigerator. Use within 7 days (or 10 days if refrigerated). Write the date on the bottle when you first mix it. If you don’t have a fridge, keep in the coolest part of your house and use within 5 days. Throw away any remaining medicine after this.
• ℹ️ Indian summer tip: In hot weather (above 35°C), always try to refrigerate the liquid medicine. If the medicine looks or smells different (changed colour, unusual smell), do not use it — get a new bottle from the pharmacy.

---

---

• If you are not feeling better after 3 days (72 hours) of taking the medicine
• If you develop any of the warning signs described above
• At the date your doctor tells you to come for review
• If the infection comes back after finishing the course
• ⚠️ Important: Even after finishing the course, if you notice yellowing of eyes or skin in the next 2 months, contact your doctor — liver side effects can sometimes appear after the medicine is stopped."

---

---

• Use ONLY the measuring cup or syringe provided — a household spoon is inaccurate and may give too little or too much medicine.
• Shake the bottle well before every dose.
• Give with food or milk to reduce tummy upset.
• Keep the medicine in the fridge after mixing.
• If your child vomits within 30 minutes of taking the medicine, give the dose again.
• Complete the full course even if the child seems well.
• Watch for: skin rash, difficulty breathing, severe diarrhoea (especially with blood), yellow eyes — go to hospital immediately if any of these occur.

• Make sure the patient takes the medicine with food, at the correct times.
• Monitor for yellow eyes/skin, dark urine, unusual confusion, or severe diarrhoea — report to doctor immediately.
• Ensure the patient drinks enough water — dehydration from diarrhoea is more dangerous in elderly patients.
• If the patient is on blood-thinning tablets (warfarin/Acitrom), watch for unusual bruising or bleeding.
• If the patient forgets doses, help set alarms or use a pill box."

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

PRICE RANGE (INR)

---

---

CLINICAL PEARLS

---

---

---

---

---

• Streptococcal pharyngitis (GAS does not produce beta-lactamase)
• Uncomplicated pneumococcal pneumonia (S. pneumoniae resistance to penicillin is via PBP modification, not beta-lactamase — clavulanate adds nothing)
• Dental prophylaxis for infective endocarditis
• Uncomplicated cystitis (if susceptible — consider nitrofurantoin/fosfomycin first)
• H. pylori eradication regimens (amoxicillin alone in triple/quadruple therapy)

---

• Fewer GI side effects (less clavulanate = less diarrhoea)
• Better compliance (2 doses vs 3 per day)
• Adequate pharmacokinetic coverage for most community-acquired infections

---

VERSION

---

REFERENCES

---

1. CDSCO Product Insert — Augmentin (Amoxicillin + Potassium Clavulanate), GlaxoSmithKline Pharmaceuticals Ltd, India. Revised product information (most recent available insert referenced).
2. CDSCO Product Insert — Amoxyclav, Cipla Ltd, India. Referenced for formulation details and Indian-specific labelling information.
3. Indian Pharmacopoeia (IP) 2022, Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Amoxicillin Trihydrate and Potassium Clavulanate Tablets / Oral Suspension / Injection.
4. National List of Essential Medicines (NLEM) India, 2022. Ministry of Health and Family Welfare, Government of India. Section: Anti-infective Medicines — Antibacterials (Beta-lactam medicines). Confirms inclusion of Amoxicillin + Clavulanic Acid (Tablet 500 mg + 125 mg; Injection 1000 mg + 200 mg).
5. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. Used for pharmacology depth, pharmacokinetic data, mechanism of action, and drug transporter profiles.
6. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapters on: Treatment of Bacterial Infections; Community-Acquired Pneumonia; Urinary Tract Infections; Skin and Soft Tissue Infections; Osteomyelitis; Intra-Abdominal Infections.

1. API (Association of Physicians of India) Textbook of Medicine, 11th Edition (2019). Chapters on: Antimicrobial Therapy; Community-Acquired Pneumonia; COPD; Urinary Tract Infections; Skin and Soft Tissue Infections; Surgical Infections; Bone and Joint Infections; Obstetric Infections; Drug-Induced Liver Injury.
2. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2nd Edition (2019). Indian Council of Medical Research, New Delhi. Referenced for empiric antibiotic recommendations, UTI management, CAP management, and surgical prophylaxis.
3. AIIMS Empiric Antibiotic Guidelines / Antibiotic Policy. All India Institute of Medical Sciences, New Delhi. Referenced for hospital-level prescribing protocols, surgical prophylaxis recommendations, and PJI management.
4. IAP (Indian Academy of Pediatrics) Guidelines. Referenced: IAP Guidelines on Acute Otitis Media (2018); IAP Guidelines on Paediatric Pneumonia; IAP Guidelines on UTI in Children; IAP Respiratory Chapter consensus on Protracted Bacterial Bronchitis (PBB).

1. ORACLE-I Trial: Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group. “Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.” Lancet. 2001;357(9261):979–988. — and — Kenyon S, Pike K, Jones DR, et al. “Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial.” Lancet. 2008;372(9646):1310–1318. Referenced for PPROM contraindication data.
2. OVIVA Trial: Li HK, Rombach I, Zamber R, et al. “Oral versus Intravenous Antibiotics for Bone and Joint Infection.” N Engl J Med. 2019;380(5):425–436. Referenced for oral step-down osteomyelitis evidence.
3. RIVUR Trial: The RIVUR Trial Investigators. “Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux.” N Engl J Med. 2014;370(25):2367–2376. Referenced for VUR prophylaxis evidence context.

1. FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines. Referenced for obstetric infection management and PPROM antibiotic recommendations.
2. National Rabies Control Programme, Government of India. Referenced for dog bite wound management context.
3. GOLD (Global Initiative for Chronic Obstructive Lung Disease) Report 2024. Referenced as supportive international source for AECOPD antibiotic recommendations.
4. NPPA (National Pharmaceutical Pricing Authority) / DPCO Price Ceiling Data. Referenced for pricing and price-control status.
5. Jan Aushadhi (PMBJP) Product Catalogue, 2024–2025. Referenced for generic brand availability and pricing at Jan Aushadhi Kendras.
6. CDSCO NSQ (Not of Standard Quality) Alerts Database — www.cdsco.gov.in. Checked for any active quality alerts on amoxicillin-clavulanate brands.
7. PvPI (Pharmacovigilance Programme of India) — Referenced for adverse drug reaction reporting protocol.
8. CDSCO Gazette Notifications on Banned FDCs (2016, 2018). Referenced for banned irrational FDC information.

---